載入...
Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations
Gilteritinib is the first FMS-like tyrosine kinase 3 (FLT3) tyrosine kinase inhibitor (TKI) approved as monotherapy in acute myeloid leukemia with FLT3 internal tandem duplication and D835/I836 tyrosine kinase domain (TKD) mutations. Sequencing studies in patients have uncovered less common, noncano...
Na minha lista:
| 發表在: | Blood Adv |
|---|---|
| Main Authors: | , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Society of Hematology
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7013266/ https://ncbi.nlm.nih.gov/pubmed/32040554 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000919 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|